Arkolith/Insider Trading/LXEO/Form 4

See Tai Sandi

Chief Development OfficerLexeo Therapeutics, Inc. (LXEO) · full profile →Form 4 · filed Aug 20, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2K
Net Open-Market Flow
-$2K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 18, 2025Sell(S)382$4.67$2K59K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-022468) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML